State Street’s Spero Therapeutics SPRO Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $475K | Hold |
214,751
| – | – | ﹤0.01% | 3603 |
|
|
2026
Q1 | $503K | Buy |
214,751
+4,600
| +2% | +$10.9K | ﹤0.01% | 3657 |
|
|
2025
Q4 | $490K | Buy |
210,151
+19,200
| +10% | +$44.6K | ﹤0.01% | 3682 |
|
|
2025
Q3 | $359K | Buy |
190,951
+37,500
| +24% | +$82.5K | ﹤0.01% | 3735 |
|
|
2025
Q2 | $445K | Buy |
153,451
+4,540
| +3% | +$6.53K | ﹤0.01% | 3640 |
|
|
2025
Q1 | $107K | Hold |
148,911
| – | – | ﹤0.01% | 3962 |
|
|
2024
Q4 | $153K | Buy |
148,911
+18,400
| +14% | +$21.9K | ﹤0.01% | 3909 |
|
|
2024
Q3 | $175K | Hold |
130,511
| – | – | ﹤0.01% | 3850 |
|
|
2024
Q2 | $170K | Hold |
130,511
| – | – | ﹤0.01% | 3866 |
|
|
2024
Q1 | $224K | Hold |
130,511
| – | – | ﹤0.01% | 3850 |
|
|
2023
Q4 | $192K | Hold |
130,511
| – | – | ﹤0.01% | 3910 |
|
|
2023
Q3 | $158K | Buy |
130,511
+19,800
| +18% | +$27.4K | ﹤0.01% | 3994 |
|
|
2023
Q2 | $161K | Hold |
110,711
| – | – | ﹤0.01% | 4069 |
|
|
2023
Q1 | $161K | Hold |
110,711
| – | – | ﹤0.01% | 4148 |
|
|
2022
Q4 | $192K | Buy |
110,711
+19,400
| +21% | +$36.2K | ﹤0.01% | 4117 |
|
|
2022
Q3 | $183K | Sell |
91,311
-9,073
| -9% | -$9.02K | ﹤0.01% | 4188 |
|
|
2022
Q2 | $74K | Sell |
100,384
-396,801
| -80% | -$1.15M | ﹤0.01% | 4630 |
|
|
2022
Q1 | $4.33M | Sell |
497,185
-346,770
| -41% | -$3.55M | ﹤0.01% | 3254 |
|
|
2021
Q4 | $13.5M | Buy |
843,955
+41,264
| +5% | +$655K | ﹤0.01% | 2734 |
|
|
2021
Q3 | $14.8M | Sell |
802,691
-8,047
| -1% | -$129K | ﹤0.01% | 2665 |
|
|
2021
Q2 | $11.3M | Sell |
810,738
-545,805
| -40% | -$7.63M | ﹤0.01% | 2847 |
|
|
2021
Q1 | $20M | Buy |
1,356,543
+1,017,712
| +300% | +$17.9M | ﹤0.01% | 2369 |
|
|
2020
Q4 | $6.57M | Buy |
338,831
+53,239
| +19% | +$830K | ﹤0.01% | 2827 |
|
|
2020
Q3 | $3.19M | Sell |
285,592
-2,982
| -1% | -$35.3K | ﹤0.01% | 3010 |
|
|
2020
Q2 | $3.9M | Buy |
288,574
+10,131
| +4% | +$114K | ﹤0.01% | 2886 |
|
|
2020
Q1 | $2.25M | Buy |
278,443
+69,852
| +33% | +$616K | ﹤0.01% | 3010 |
|
|
2019
Q4 | $2.01M | Buy |
208,591
+11,365
| +6% | +$123K | ﹤0.01% | 3245 |
|
|
2019
Q3 | $2.09M | Buy |
197,226
+27,695
| +16% | +$292K | ﹤0.01% | 3203 |
|
|
2019
Q2 | $1.95M | Buy |
169,531
+60,396
| +55% | +$727K | ﹤0.01% | 3250 |
|
|
2019
Q1 | $1.4M | Sell |
109,135
-42,958
| -28% | -$456K | ﹤0.01% | 3269 |
|
|
2018
Q4 | $935K | Buy |
152,093
+24,168
| +19% | +$196K | ﹤0.01% | 3341 |
|
|
2018
Q3 | $1.34M | Buy |
127,925
+66,727
| +109% | +$774K | ﹤0.01% | 3356 |
|
|
2018
Q2 | $898K | Buy |
61,198
+29,525
| +93% | +$378K | ﹤0.01% | 3414 |
|
|
2018
Q1 | $451K | Buy |
+31,673
| New | +$384K | ﹤0.01% | 3447 |
|
Other funds holding SPRO
GP
P
VCM
AI
VFT
GCP
State Street's SPRO Position: Q2 2026 in Review
State Street held its Spero Therapeutics (SPRO) position steady in Q2 2026 at 214,751 shares worth $475K. The position accounts for ﹤0.01% of the portfolio, ranked #3603.
State Street first reported a position in SPRO in Q1 2018 and has held it in 34 quarters since. The position peaked at $20M in Q1 2021. 34 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.
- State Street held 214,751 shares of Spero Therapeutics worth $475K as of Q2 2026.
- State Street left its Spero Therapeutics share count unchanged in Q2 2026.
- Spero Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3603 holding.
- State Street first reported a position in Spero Therapeutics in Q1 2018 and has held it in 34 quarters since.
- State Street's Spero Therapeutics position peaked at $20M in Q1 2021.
- 34 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.
Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.